肺功能对自体造血干细胞移植患者的影响
该研究回顾性分析了629例接受auto-HSCT的患者,其中334例采用BEAM方案,295例采用大剂量美法仑方案。多因素分析显示,DLCOcSB≤60%预计值是两种方案下总生存期降低的独立危险因素,且与无复发生存率降低及非复发死亡(包括肺部原因)相关。
要点
- DLCOcSB≤60%预计值是BEAM或大剂量美法仑预处理患者OS降低的独立危险因素。
- DLCOcSB≤60%预计值与肺毒性药物、纵隔放疗、KPS≤80%、吸烟史及ICU治疗相关。
- DLCOcSB≤60%预计值患者更常发生非复发死亡,包括肺部原因死亡。
核心结论
- DLCOcSB≤60%预计值是接受BEAM或大剂量美法仑预处理auto-HSCT患者总生存期降低的独立危险因素。
研究设计与样本
- 回顾性分析2007年至2017年单中心629例接受auto-HSCT的患者,334例BEAM预处理,295例大剂量美法仑预处理。
- BEAM组中位随访52个月(范围0.2-152),大剂量美法仑组中位随访50个月(范围0.5-149)。
主要发现
- BEAM组多因素分析显示,疾病进展、DLCOcSB≤60%预计值、KPS≤80%、HCT-CI评分≥4及年龄>70岁与OS降低相关。
- 大剂量美法仑组多因素分析显示,DLCOcSB≤60%预计值、HCT-CI评分≥4及年龄>60岁与OS降低相关。
- DLCOcSB≤60%预计值与肺毒性物质化疗、纵隔放疗、KPS≤80%、当前或既往吸烟及ICU治疗相关。
- DLCOcSB≤60%预计值患者更常发生非复发死亡,包括肺部原因死亡。
临床怎么用
- auto-HSCT前应评估DLCOcSB,DLCOcSB≤60%预计值提示OS降低风险,可辅助风险分层与知情决策。
局限性
- 本研究为单中心回顾性分析,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation (auto-HSCT), is an established therapy for patients with hematological malignancies. The age of patients undergoing auto-HSCT and, therefore, the comorbidities, has increased over the last decades. However, the assessment of organ dysfunction prior to auto-HSCT has not been well studied. Therefore, we retrospectively analyzed the association of clinical factors and lung and cardiac function with outcome and complications after conditioning with BEAM (BCNU/carmustine, etoposide, cytarabine, melphalan) or high-dose melphalan in patients undergoing auto-HSCT. This study included 629 patients treated at our institution between 2007 and 2017; 334 and 295 were conditioned with BEAM or high-dose melphalan, respectively. The median follow-up was 52 months (range, 0.2-152) and 50 months (range, 0.5-149), respectively. In the multivariate analysis, we identified that progressive disease, CO-diffusion capacity corrected for hemoglobin (DLCOcSB) ≤ 60% of predicted, Karnofsky Performance Status (KPS) ≤ 80%, Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score ≥ 4, and age > 70 years were associated with decreased overall survival (OS) in patients treated with BEAM. Similarly, DLCOcSB ≤ 60% of predicted, HCT-CI score ≥ 4, and age > 60 years were identified in patients treated with high-dose melphalan. Abnormalities in DLCOcSB ≤ 60% of predicted were associated with chemotherapy with lung-toxic substances, mediastinal radiotherapy, KPS ≤ 80%, current/previous smoking, and treatment in the intensive care unit. More often, patients with DLCOcSB ≤ 60% of predicted experienced nonrelapse mortality, including pulmonary causes of death. In summary, we identified DLCOcSB ≤ 60% of predicted as an independent risk factor for decreased OS in patients conditioned with BEAM or high-dose melphalan prior to auto-HSCT.
引用
- Duque-Afonso J, Ewald S, Ihorst G, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021. PMID: 34610094. doi:10.1182/bloodadvances.2021004863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。